Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Preusser, Matthias [VerfasserIn]   i
 Capper, David [VerfasserIn]   i
 Deimling, Andreas von [VerfasserIn]   i
 Winkler, Frank [VerfasserIn]   i
 Wick, Wolfgang [VerfasserIn]   i
Titel:Brain metastases
Titelzusatz:pathobiology and emerging targeted therapies
Verf.angabe:Matthias Preusser, David Capper, Aysegül Ilhan-Mutlu, Anna Sophie Berghoff, Peter Birner, Rupert Bartsch, Christine Marosi, Christoph Zielinski, Minesh P. Mehta, Frank Winkler, Wolfgang Wick, Andreas von Deimling
E-Jahr:2012
Jahr:February 2012
Umfang:18 S.
Fussnoten:Gesehen am 28.11.2018
Titel Quelle:Enthalten in: Acta neuropathologica
Ort Quelle:Berlin : Springer, 1961
Jahr Quelle:2012
Band/Heft Quelle:123(2012), 2, Seite 205-222
ISSN Quelle:1432-0533
Abstract:Brain metastases (BM) are common in cancer patients and are associated with high morbidity and poor prognosis, even after intensive multimodal therapy including resection, radiotherapy (stereotactic radiosurgery or whole brain radiotherapy) and chemotherapy. However, advances in the understanding of the pathobiology of BM and the development of molecular targeted agents hold promise for improved prophylaxis and therapy of BM. Here we provide a comprehensive review of the current concepts on mechanisms of the brain-metastatic cascade involving hematogenous dissemination of tumor cells, attachment to microvessel endothelial cells, extravasation into the brain, interaction with the local microenvironment, angiogenesis and intraparenchymal proliferation. Transendothelial migration depends on adhesion molecules such as integrins, selectins and chemokines. Tumor cells invade the brain by degrading extracellular matrix components using heparanase and matrix metalloproteinases. Astrocytes and microglial cells exert not only anti-, but also pro-neoplastic effects on brain-invading tumor cells. Some tumor types (e.g. melanoma) show prominent cooption of preexisting vasculature, while other tumor types (e.g. lung cancer) tend to show early angiogenesis after brain invasion. In this article we also critically summarize the data on currently studied targeted therapeutics in BM especially in the context of recent preclinical data. The most promising agents for BM patients include anti-angiogenic drugs, inhibitors of v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) for BRAF V600E mutated melanoma and inhibitors of epithelial growth factor receptor for non-small cell lung cancer. Molecular analysis of the BRAF V600E status of melanoma BM using DNA-based methods or immunohistochemistry may soon enter the routine neuropathological practice.
DOI:doi:10.1007/s00401-011-0933-9
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: http://dx.doi.org/10.1007/s00401-011-0933-9
 Volltext: https://doi.org/10.1007/s00401-011-0933-9
 DOI: https://doi.org/10.1007/s00401-011-0933-9
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Brain metastases
 Cancer
 Molecular targets
 Pathobiology
 Therapy
K10plus-PPN:1584606339
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68333467   QR-Code
zum Seitenanfang